Protagonist Therapeutics, Inc.
As of Oct 22, 2026, Protagonist Therapeutics is in Stage 2, the uptrend phase, now in week 31 (since Mar 16, 2026). It closed at $139.53, 12.0% below its 52-week high and above its 200-day average, which is rising.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is PTGX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PTGX among Biotechnology58th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …58 | PTGX | Stage 2 · wk 31 | 93 | +0.6% |
Protagonist Therapeutics: quick answers
What stage is Protagonist Therapeutics in?
As of Oct 22, 2026, Protagonist Therapeutics (PTGX) is in Stage 2, the uptrend phase. It entered Stage 2 on Mar 16, 2026 and is in week 31. What the four stages mean
Is Protagonist Therapeutics in an uptrend?
Yes. Protagonist Therapeutics is in a Stage 2 uptrend. It trades 21.5% above its 200-day average, which is rising.
How far is Protagonist Therapeutics from its 52-week high?
Protagonist Therapeutics closed at $139.53 on Oct 22, 2026, 12.0% below its 52-week high of $158.62. Its 52-week low is $73.50.
How has Protagonist Therapeutics performed over the past year?
As of Oct 22, 2026, Protagonist Therapeutics is up 86.0% over the past year and up 60.0% so far in 2026.
Which sector and industry is Protagonist Therapeutics in?
Protagonist Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.